Abstract Neurofibromatosis type 2 (NF2) is a tumour-prone disorder characterised by the
development of multiple schwannomas and meningiomas. Prevalence (initially estimated at …

Introduction: Vestibular schwannomas (VS) account for approximately 85% of tumors in the
cerebello-pontine angle, with a lifetime incidence of approximately 1 in 1000. Most are …

The conserved Hippo signaling pathway regulates organ size in Drosophila and mammals.
While a core kinase cascade leading from the protein kinase Hippo (Hpo)(Mst1 and Mst2 in …

Abstract Neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and
schwannomatosis (SWN) are tumor-suppressor syndromes. Each syndrome is an orphan …

This single-institution phase II study was performed to estimate the response rate to lapatinib
in neurofibromatosis type 2 (NF2) patients with progressive vestibular schwannoma (VS) …

Background Neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), familial adenomatous
polyposis (FAP), von Hippel-Lindau syndrome (VHL), and Gorlin syndrome (GS) are single …

Genetic alterations of neurofibromatosis type 2 (NF2) gene lead to the development of
schwannomas, meningiomas, and ependymomas. Mutations of NF2 gene were also found …

Abstract Neurofibromatosis type 2 (NF2) is a rare genetic disorder predisposing to multiple
benign tumors of the nervous system. Meningiomas occur in about half of NF2 patients, and …

Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder (incidence 1: 33 000-
40 000) characterized by formation of central nervous system tumors, due to mutation in the …

Background Activation of the mammalian target of rapamycin (mTOR) signaling pathway is
thought to be a key driver of tumor growth in Merlin (NF2)-deficient tumors. Everolimus is an …